URCC21038: DiRECT Trial — Enhancing Cancer Care Through Diversity by Studying Immunotherapy Outcomes Across Populations

Study Overview:
 The DiRECT trial investigates how immune checkpoint inhibitors affect treatment response and survival across diverse racial and ethnic groups. By collecting biological samples and treatment data, researchers aim to understand why some populations respond differently and to reduce disparities in cancer care.

Key Study Details:

• Phase & Design: Observational

• Population: Patients receiving checkpoint inhibitor immunotherapy

• Treatment Arms: Data and biospecimen collection only

• Primary Objective: Examine racial and ethnic differences in treatment outcomes

• Why It Matters: Findings could lead to more personalized immunotherapy approaches and improved equity in cancer treatment.